Hitting the Reset Button on Cellular Aging

Episode Summary

Executive Summary: The episode features Genevity CEO John Hochman explaining how the company uses AI and large public omics datasets to identify dysregulated transcription factors as drug targets for aging-related diseases. The discussion centers on Reset, Genevity’s computational platform, and lead siRNA programs for type 2 diabetes and obesity that aim for infrequent dosing, improved adherence, and durable metabolic benefits.

Main Topics: Transcription factors and healthy biology (Priority: 5/5): Hochman explains transcription factors as master regulators that interpret signals and control which genes are expressed, helping maintain homeostasis and guide development. How transcriptional dysregulation drives disease (Priority: 5/5): The conversation details how aging and environmental stress can shift transcription factor activity, creating downstream dysfunction that contributes to chronic disease, including cancer and metabolic disorders. Genevity’s Reset AI platform (Priority: 5/5): Reset uses large-scale human omics and public datasets to infer which transcription factors are driving disease by analyzing regulon/network changes across many patients. From computational target discovery to therapeutic candidates (Priority: 4/5): Genevity describes a workflow that goes from ranked transcription factor targets to in vitro testing, in vivo studies, and siRNA optimization to produce a development candidate. Lead programs in type 2 diabetes and obesity (Priority: 5/5): The company’s most advanced assets are siRNA programs for diabetes and obesity, delivered via liver-targeted GalNAc or broader tissue targeting, with the goal of low-frequency dosing and durable efficacy. Differentiation versus GLP-1 therapies (Priority: 4/5): Hochman argues Genevity’s therapies could complement or improve on GLP-1s by reducing dosing burden, improving adherence, preserving muscle, and sustaining effects after discontinuation. Funding strategy and runway (Priority: 3/5): Genevity raised capital from nontraditional investors and says its current runway extends into 2027, enough to support at least one initial clinical study.

Key Arguments: Transcription factors are central regulators of cellular programs and therefore plausible disease drivers when they become dysregulated with age or stress. Complex diseases of aging may be better addressed by network-level, transcriptional analysis than by focusing on single biomarkers or single-pathway models. Public omics datasets are sufficient to discover novel targets when analyzed with machine learning and network-based methods like Reset. Type 2 diabetes and obesity are attractive initial indications because they are common, biologically heterogeneous but driven by sufficiently shared transcriptional programs, and can show preclinical proof of concept relatively quickly. siRNA is a practical modality for targeting transcription factors despite historical assumptions that such proteins are “undruggable.” Genevity’s approach could improve upon GLP-1s by offering less frequent dosing, better adherence, less rebound after stopping therapy, and potentially less muscle loss. The company believes it can reach human proof of concept with existing capital while retaining flexibility to raise more before or during clinical development.

Data Points: Share of genes that are transcription factors: About 10% - Hochman describes transcription factors as a broad protein class throughout the genome. Type 2 diabetes driven by diet/exercise factors: 80% to 90% - He says most type 2 diabetes cases are driven by food intake and lack of exercise, supporting a more homogeneous disease-driving pattern. siRNA sequences generated per target: About 2,000 - Genevity’s optimization workflow reportedly creates thousands of candidate siRNA sequences before narrowing to top candidates. Adherence after 1 year on GLP-1s in a UK study: 64.5% - Used to illustrate that weekly injection regimens still face substantial discontinuation or nonadherence. Adherence after 2 years on GLP-1s in a UK study: About 60% - Further evidence of long-term adherence challenges. Partial or full discontinuations after 1-2 years: 50% to 60% - Supports the argument that current obesity therapies face persistence problems. Weight regained after stopping GLP-1s: About 70% within a year - Cited to show rebound effects and the need for longer-lasting therapies. Company funding raised earlier in the year: $10 million - Genevity’s announced financing round. Runway: Through 2027 - Hochman says current capital should support development including an initial clinical study. Potential dosing frequency: Every 6 to 12 months - Claimed for both diabetes and obesity programs based on preclinical/human data discussed in the interview.

Pivotal Quotes: "Transcription factors are almost like a manager within the body." — John Hochman: He uses an analogy to explain how transcription factors coordinate gene expression and cellular programs. "We're taking it more like a large language model or machine learning approach and saying, here's the data." — John Hochman: Describing the Reset platform’s AI-driven, network-based discovery strategy. "The effect still lasts. And so you're not seeing the rebound." — John Hochman: Referring to the obesity program’s preclinical durability after treatment discontinuation.

Implications: Genevity is betting that transcription-factor targeting plus AI-driven target discovery can open a new class of aging-disease therapies. If successful, its low-frequency siRNA drugs could complement GLP-1s and improve long-term metabolic care.